| Bioactivity | Nadunolimab is a human monoclonal IgG1 antibody targeting IL1RAP. Nadunolimab blocks IL-1α and IL-1β signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research of cancer[1]. |
| Invitro | Nadunolimab (20 µg/mL; 30 min and 1 h; A549 cells and BxPC3 cells) reduces IL-1α-induced release of pro-infamma tory cytokines and chemokines, including IL-1β, IL-6 TNF-α and MIP-1α, and CXCL1[1]. |
| In Vivo | Nadunolimab (10 mg/kg; i.p.; twice on day 1 and thereafter twice weekly; nude BALB/c mice with LU2503 or MC38 tumors) improves the anti‑tumor efficacy of chemotherapy and blocks both murine IL-1α and IL-1β signaling[1]. Animal Model: |
| Name | Nadunolimab |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. |